Psoriasis Guru

...Itching for a Cure

Psoriasis News

...now browsing by tag

 
 

Genetic Testing by PsoriasisDX Offers Early Psoriatic Arthritis Detection

Thursday, October 1st, 2009

PsoriasisDX, a subsity of PharmaGenoma, has released a genetic testing kit that will help doctors to detect psoriatic arthritis. By detecting this condition early much irreversible joint damage can be prevented.

Cost for the kit: $399.00.

It involves taking a cheek swab test, which is then packaged up and sent to a PsoriasisDX laboratory for testing.  The lab then tests for an immune response gene variant called MICA-A9 (or MICA, for short).  Different independent studies have confirmed that subjects who have this gene variant tend to develop psoriatic arthritis (likelihood of 60%).

The logical question now would be: “Exactly how do I prevent psoriatic arthritis (or psoriasis in general)?”

Answer:  Keep reading this blog!

***

Psoriatic arthritis affects about 20% of all people who have psoriasis.  It’s symptoms are similar in many ways to other forms of arthritis, though with a tendency to affect fewer joints and, of course, the fundamental cause is different.  Other symptoms include debilitating pain, swelling and joint deformation over longer periods of time.

Psoriasis News: Stelara Is Now FDA Approved

Thursday, October 1st, 2009

A few days ago I wrote an article anticipating the eventually approved of Stelara by the FDA and now… it is done.  As of right now, you can obtain this groundbreaking new psoriasis treatment in the UK, the general European Union, Canada and the United States for the treatment of moderate to sever plaque psoriasis (the most common type of psoriasis) by prescription only.

Stelara (a product of Johnson and Johnson) is groundbreaking for the dramatic improvements it produces in people suffering from plaque psoriasis (70% improvement according to FDA sanctioned tests), convenient dosing (5 shots per year) and it seems to pose very mild, if any, side effects.  It is a selective immunosuppressant… which is to say that it is designed to target and suppress only certain proteins (interleukin-12 and interleukin-23), which are key players in creating the symptoms of plaque psoriasis.  The active ingredient is called ustekinumab.

As you might be able to guess by the word “immunosuppressant,” however, Stelara is the kind of drug that can open you up to infections that otherwise would have been held off by your body”s natural defenses.

Most researchers have believed for a while now that psoriasis throws off the immune system, causing an excess of skin cell production, which results in the itchy, red, scaly, irritated skin symptoms that have made this disease notorious.  This is why drug companies have been focusing on drugs that either alter or suppress the body’s immune system.  Altering the immune system is one of the most direct ways medical professionals know of to attack psoriasis.

Also of note: Stelara is supposed to be very expensive, upwards of $16,000 per year (if you had to pay for the whole thing out of pocket).  My optimistic guess for why it would cost this much (for 5 doses) is that a lot of money was poured into research and development, thus a high cost is needed to recoup.  Of course, drug companies are businesses first and foremost, so this is probably also a factor.  But if Stelara works and people are willing to pay, then I guess it is worth it.

My psoriasis is not nearly severe enough to justify using this drug (right now anyway).  My game plan as of now is to seek out natural, less expensive, lifestyle oriented solutions to root out the disease and keep it rooted out.

Tim Gunn of Project Runway Launches the Addressing Psoriasis Campaign

Monday, September 28th, 2009

Thanks to Tim Gunn (host of Project Runway), the Addressing Psoriasis campaign is off to a strong start.  The two main goals of this campaign are to raise awareness about the disease for those who don’t have it and provide additional resources / encouragement for those who do have it.

The Addressing Psoriasis campaign aims at dispelling many of the myths about the psoriasis, such as whether it is contagious (it isn’t).  Also, many of us who have psoriasis need to be reminded that there are a variety of treatments out there — we shouldn’t stop researching and searching for new more effective strategies to battle this condition.

Tim Gunn presided over the Addressing Psoriasis Fashion Show, during which 8 models (all of whom suffered from moderate to sever plaque psoriasis) walked down the catwalk wearing new custom-designed outfits courtesy of up and coming designers at the Fashion Institute of Technology.

You can see all the models and designers involved as well as a short video documenting the vent at AddressPsoriasis.com.

New Psoriasis Drug from Johnson and Johnson: Stelara (Ustekinumab)

Monday, September 28th, 2009

The National Institute for Health and Clinical Excellence (NICE) has approved Johnson and Johnson’s new psoriasis drug, Stelara, for use in the U.K.  The drug has also been approved for use in Canada but is still under review by the FDA.

It’s also expensive:  10,000 pounds, or about $16,000 USD per year.

Stelara works by targeting two specific proteins that play a major role in the body’s immune system: Interleukin 12 and Interleukin 23.  Regulating these proteins should reduce swelling and bring excessive skin cell production under control.

Administering this new drug should prove to be much more convenient than most other psoriasis treatments — it only needs to be taken 5 times a year via injection.  Thus far it has also proven to be safe.

In light of the unpredictable nature of psoriasis it is good to have as many treatment options, or as many avenues of attack, as possible.  In addition to developing resistance to certain treatments over time, psoriasis can also behave differently depending on the individual in question.  A treatment that works well for one individual might not work for another person and visa versa.

At this stage in the game Stelara is meant to treat moderate to severe plaque psoriasis (this is the most common type of psoriasis).  It is viewed as an option that should be tried only after other alternatives have proved to be ineffective.  This will most likely include a large percentage of the masses who currently suffer from psoriasis since so many are at their wits’ end trying to find an effective treatment for it.